A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high
 risk patients with complete remission of diffuse large B lymphoma / stage III follicular
 lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin,
 vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen
Inclusion Criteria:

 1. Male or female patient age >14 years old;

 2. Pathological types include: diffuse large B lymphoma, and stage III follicular
 lymphoma;

 3. At the initial stage of therapy, received standard R-CHOP regimen and complete
 remission after the first course of treatment;

 4. After complete remission, not consider to receive hematopoietic stem cell
 transplantation or chimeric antigen receptor T cell immunotherapy;

 5. Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase
 (SGPT) not exceed 2 times of the normal upper limit;

 6. Serum total bilirubin and creatinine not exceed 1.5 times of the normal upper limit;

 7. Serum creatinine not exceed 1.5mg/dl;

 8. Patients with high risk factors, including age > 60 year, or with diabetes/ impaired
 glucose tolerance, or with International Prognostic Index (IPI) score ≥2.

 9. Sign informed consent file.

 Exclusion Criteria:

 1. Past medical history of high doses of cytarabine, methotrexate and rituximab
 maintenance therapy;

 2. Past medical history of any type of hematopoietic stem cell transplantation;

 3. Past medical history of lactic acidosis;

 4. Extreme weight loss failure, malnutrition or dehydration patients;

 5. Pregnant women or lactating women, or women who do not take contraceptive measures for
 childbearing age;

 6. Alopecia, mental retardation or psychiatric disorders that affect the patient's normal
 informed consent;

 7. Type 1.2 diabetes with ketoacidosis, liver function or renal insufficiency, pulmonary
 insufficiency, heart failure, acute myocardial infarction, severe infection and
 trauma, major surgery and clinical hypotension or hypoxia;

 8. Diabetes complicated with severe chronic complications (such as diabetic nephropathy,
 diabetic retinopathy);

 9. Any other serious complications occurred, depending on the outcome of the study;

 10. Before the intravenous pyelography or anterior angiography;

 11. Alcoholics;

 12. Deficiency of Vitamin B12, folic acid or iron.